Abivax

Contributing Author

Recent Articles by Abivax

10 hours	Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (702M) Public Offering of American Depositary Shares ABVX GlobeNewswire
10 hours	Abivax announces trading resumption of its ordinary shares on Euronext Paris ABVX GlobeNewswire
10 hours	Abivax Announces Pricing of Oversubscribed and Upsized $800M (702M) Public Offering of American Depositary Shares ABVX GlobeNewswire
17 hours	Abivax announces temporary trading halt of its ordinary shares on Euronext Paris ABVX GlobeNewswire
Jun-30	Abivax Announces Launch of Public Offering of American Depositary Shares ABVX +38.60% GlobeNewswire
Jun-29	Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database ABVX GlobeNewswire
Jun-01	Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis ABVX ABVX -44.10% GlobeNewswire
May-22	Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis ABVX GlobeNewswire
May-11	Abivax Announces Results of its May 11, 2026 Annual General Meeting ABVX GlobeNewswire
May-05	Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (38.5M) Offering of American Depositary Shares ABVX +5.68% GlobeNewswire
Apr-22	Abivax to Present Data on Obefazimod at Digestive Disease Week ABVX GlobeNewswire
Apr-20	Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents ABVX GlobeNewswire
Apr-01	Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies ABVX GlobeNewswire
Mar-23	Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABVX GlobeNewswire
Feb-21	Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 ABVX GlobeNewswire
Jan-07	Abivax Provides 2026 Corporate Outlook ABVX +6.20% ABVX -8.69% GlobeNewswire
Dec-18	Abivax to be Added to Nasdaq Biotechnology Index ABVX GlobeNewswire
Dec-17	Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings ABVX GlobeNewswire
Dec-15	Abivax Presents Third Quarter 2025 Financial Results ABVX -6.08% ABVX -5.88% GlobeNewswire
Nov-03	Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis ABVX GlobeNewswire
Oct-06	Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies ABVX GlobeNewswire
Oct-05	Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data ABVX GlobeNewswire
Sep-29	Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting ABVX GlobeNewswire
Sep-23	Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting ABVX GlobeNewswire
Sep-12	Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review ABVX GlobeNewswire
Sep-08	Abivax Presents First Half 2025 Financial Results ABVX GlobeNewswire
Jul-28	Abivax Announces Closing of $747.5 Million Public Offering ABVX GlobeNewswire
Jul-25	Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (637.5M) ABVX GlobeNewswire
Jul-24	Abivax announces trading resumption of its ordinary shares on Euronext Paris ABVX GlobeNewswire
Jul-24	Abivax Announces Pricing of $650M (554M) Public Offering of American Depositary Shares ABVX GlobeNewswire
Jul-24	Abivax announces temporary trading halt of its ordinary shares on Euronext Paris ABVX GlobeNewswire
Jul-23	Abivax Announces Launch of Public Offering ABVX +586.00% GlobeNewswire
Jul-22	Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis ABVX GlobeNewswire
Jun-11	Abivax Announces Results of its June 6, 2025 Annual General Meeting ABVX -5.72% ABVX -5.39% GlobeNewswire
Jun-02	Abivax Presents First Quarter 2025 Financial Results ABVX +5.48% ABVX +21.89% GlobeNewswire

Abivax

Recent Articles by Abivax

Upgrade your Finviz experience